← Oncology Approval Tracker

FDA DECISION ·

Ermeza oral solution

levothyroxine sodium · Mylan Pharmaceuticals / Viatris

FDA approvalNew formulationDifferentiated thyroid cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

An oral levothyroxine solution for thyrotropin suppression as an adjunct to surgery and radioiodine in patients with thyrotropin-dependent well-differentiated thyroid cancer, including pediatric patients.

LAMPGEN ANALYSIS

Why it matters

The formulation supplies an additional way to deliver thyroid-hormone suppression after definitive treatment.

What research teams should watch

Record the formulation, target TSH and thyroid-function follow-up schedule when reconciling cancer-related use.

PRIMARY RECORDS

Sources